JP2018509908A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018509908A5 JP2018509908A5 JP2017548953A JP2017548953A JP2018509908A5 JP 2018509908 A5 JP2018509908 A5 JP 2018509908A5 JP 2017548953 A JP2017548953 A JP 2017548953A JP 2017548953 A JP2017548953 A JP 2017548953A JP 2018509908 A5 JP2018509908 A5 JP 2018509908A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- drug
- host cell
- seq
- following formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562134981P | 2015-03-18 | 2015-03-18 | |
| US62/134,981 | 2015-03-18 | ||
| PCT/US2016/022943 WO2016149535A1 (en) | 2015-03-18 | 2016-03-17 | Cd48 antibodies and conjugates thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020091335A Division JP2020141700A (ja) | 2015-03-18 | 2020-05-26 | Ｃｄ４８抗体及びその複合体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018509908A JP2018509908A (ja) | 2018-04-12 |
| JP2018509908A5 true JP2018509908A5 (enExample) | 2019-03-07 |
| JP6892826B2 JP6892826B2 (ja) | 2021-06-23 |
Family
ID=56919489
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017548953A Expired - Fee Related JP6892826B2 (ja) | 2015-03-18 | 2016-03-17 | Ｃｄ４８抗体及びその複合体 |
| JP2020091335A Pending JP2020141700A (ja) | 2015-03-18 | 2020-05-26 | Ｃｄ４８抗体及びその複合体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020091335A Pending JP2020141700A (ja) | 2015-03-18 | 2020-05-26 | Ｃｄ４８抗体及びその複合体 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US10722592B2 (enExample) |
| EP (2) | EP3270965B1 (enExample) |
| JP (2) | JP6892826B2 (enExample) |
| KR (1) | KR20170128256A (enExample) |
| CN (1) | CN107530422B (enExample) |
| AU (1) | AU2016232839B2 (enExample) |
| BR (1) | BR112017019617A2 (enExample) |
| CA (1) | CA2976740A1 (enExample) |
| DK (1) | DK3270965T3 (enExample) |
| EA (2) | EA035374B1 (enExample) |
| ES (1) | ES2795818T3 (enExample) |
| IL (1) | IL254027B (enExample) |
| MX (1) | MX382582B (enExample) |
| SG (1) | SG11201706786UA (enExample) |
| WO (1) | WO2016149535A1 (enExample) |
| ZA (1) | ZA201705935B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3433278A4 (en) | 2016-03-25 | 2019-11-06 | Seattle Genetics, Inc. | METHOD FOR THE PRODUCTION OF PEGYLATED ACTIVE LINKERS AND INTERMEDIATE PRODUCTS THEREOF |
| JP7527787B2 (ja) | 2017-03-24 | 2024-08-05 | シージェン インコーポレイテッド | グルクロニド薬物－リンカーの調製のためのプロセスおよびその中間体 |
| CN112166115A (zh) | 2018-05-29 | 2021-01-01 | 尹图赛利有限公司 | 新型苯二氮杂*衍生物及其用途 |
| TWI920652B (zh) | 2018-06-07 | 2026-04-01 | 美商思進公司 | 喜樹鹼結合物 |
| EP3873912B1 (en) | 2018-10-31 | 2026-03-25 | Intocell, Inc. | Fused heterocyclic benzodiazepine derivatives and uses thereof |
| JP7754715B2 (ja) | 2019-02-05 | 2025-10-15 | シージェン インコーポレイテッド | 抗ｃｄ２２８抗体及び抗体薬物コンジュゲート |
| EP3980423A1 (en) | 2019-06-10 | 2022-04-13 | Sutro Biopharma, Inc. | 5h-pyrrolo[3,2-d]pyrimidine-2,4-diamino compounds and antibody conjugates thereof |
| BR112022005114A2 (pt) | 2019-10-04 | 2022-06-21 | Seagen Inc | Anticorpo, composição farmacêutica, métodos para tratar câncer e para produzir um conjugado anticorpo-fármaco e um anticorpo, ácido nucleico, vetor, célula hospedeira, e, conjugado anticorpo-fármaco |
| KR20220079606A (ko) | 2019-10-04 | 2022-06-13 | 씨젠 인크. | 캄프토테신 펩티드 접합체 |
| WO2021067820A1 (en) | 2019-10-04 | 2021-04-08 | Seagen Inc. | Formulation of antibody-drug conjugate |
| AU2021251875A1 (en) | 2020-04-10 | 2022-11-03 | Seagen Inc. | Charge variant linkers |
| JP2023553808A (ja) * | 2020-11-24 | 2023-12-26 | ノバルティス アーゲー | Ｍｃｌ－１阻害剤抗体－薬物コンジュゲートおよび使用方法 |
| MX2023006010A (es) * | 2020-11-24 | 2023-06-08 | Novartis Ag | Anticuerpos anti-cd48, conjugados de anticuerpo-farmaco, y usos de los mismos. |
| JP2024510435A (ja) | 2021-03-18 | 2024-03-07 | シージェン インコーポレイテッド | 生体活性化合物の内部移行複合体からの選択的薬物放出 |
| IL308795A (en) | 2021-05-28 | 2024-01-01 | Seagen Inc | Anthracycline antibody conjugates |
| KR20250004952A (ko) | 2022-03-17 | 2025-01-08 | 씨젠 인크. | 캄프토테신 접합체 |
| WO2024129756A1 (en) | 2022-12-13 | 2024-06-20 | Seagen Inc. | Site-specific engineered cysteine antibody drug conjugates |
| LT4601703T (lt) | 2023-04-18 | 2026-06-25 | Astrazeneca Ab | Konjugatai, apimantys atskeliamuosius jungtukus |
| TW202525344A (zh) | 2023-08-15 | 2025-07-01 | 瑞典商阿斯特捷利康公司 | 包含可切割連接子的軛合物 |
| TW202535940A (zh) | 2023-10-24 | 2025-09-16 | 美商思進公司 | 化學治療化合物及使用方法 |
| WO2025149947A1 (en) | 2024-01-12 | 2025-07-17 | Seagen Inc. | Antibody-drug conjugates |
| WO2025185617A1 (en) * | 2024-03-05 | 2025-09-12 | Hutchmed Limited | Linker, antibody-drug conjugate and use thereof |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| WO1997035614A1 (en) * | 1996-03-27 | 1997-10-02 | Crc For Biopharmaceutical Research Pty. Ltd. | The use of antibodies against cd48 for the treatment of t and b cell lymphomas and leukemias |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| AU2002368077B2 (en) | 2001-07-12 | 2010-03-04 | Jefferson Foote | Super humanized antibodies |
| ES2369542T3 (es) | 2002-07-31 | 2011-12-01 | Seattle Genetics, Inc. | Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa. |
| ES2605443T3 (es) | 2003-11-06 | 2017-03-14 | Seattle Genetics, Inc. | Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia |
| JPWO2005094886A1 (ja) * | 2004-03-31 | 2008-02-14 | キリンファーマ株式会社 | Ｇｐｉアンカー蛋白質アゴニストによる調節性ｔ細胞分化誘導・増殖方法およびそのための医薬組成物 |
| EP1747237A4 (en) * | 2004-04-16 | 2008-05-21 | Macrogenics Inc | SPECIFIC GAMMA FC ANTIBODIES AND METHODS OF USING THE SAME |
| WO2007008848A2 (en) | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus |
| ES2708763T3 (es) | 2005-07-07 | 2019-04-11 | Seattle Genetics Inc | Compuestos de monometilvalina que tienen modificaciones de la cadena lateral de fenilalanina en el extremo C |
| HUE035853T2 (en) | 2005-07-18 | 2018-05-28 | Seattle Genetics Inc | Beta-glucuronide-linker-drug conjugates |
| SI1964852T1 (sl) * | 2005-12-20 | 2013-09-30 | Sbi Biotech Co. Ltd. | Proti-ilt7 protitelo |
| CN101903403B (zh) | 2007-10-19 | 2016-03-16 | 西雅图基因公司 | Cd19结合剂及其应用 |
| MX2010005282A (es) * | 2007-11-13 | 2010-08-31 | Teva Pharma | Anticuerpos humanizados contra tl1a. |
| WO2009099580A2 (en) * | 2008-02-05 | 2009-08-13 | Monsanto Technology, Llc | Isolated novel nucleic acid and protein molecules from soy and methods of using those molecules to generate transgenic plants with enhanced agronomic traits |
| US9097717B2 (en) | 2009-04-10 | 2015-08-04 | Osaka University | Methods of killing myeloma stem and precursor cells by administering anti-CD48 antibodies |
| EP2287197A1 (en) * | 2009-08-21 | 2011-02-23 | Pierre Fabre Medicament | Anti-cMET antibody and its use for the detection and the diagnosis of cancer |
| AR083044A1 (es) * | 2010-09-27 | 2013-01-30 | Regeneron Pharma | Anticuerpos anti-cd48 y usos de los mismos |
| RU2623161C2 (ru) * | 2011-04-15 | 2017-06-22 | Компуджен Лтд. | Полипептиды и полинуклеотиды и их применение для лечения иммунологических нарушений и рака |
| CA2866612C (en) * | 2012-03-08 | 2018-01-16 | Halozyme, Inc. | Conditionally active ph-dependent cetuximab variant anti-epidermal growth factor receptor antibodies and method of use thereof |
| CN104822656B (zh) * | 2012-05-15 | 2018-05-01 | 西雅图基因公司 | 自稳定接头偶联物 |
| PT3057585T (pt) * | 2013-10-15 | 2020-10-21 | Seagen Inc | Fármaco-ligadores peguilados para farmacocinética melhorada de conjugados de fármaco-ligando |
-
2016
- 2016-03-17 KR KR1020177024226A patent/KR20170128256A/ko not_active Withdrawn
- 2016-03-17 EP EP16765773.3A patent/EP3270965B1/en not_active Not-in-force
- 2016-03-17 EP EP19219476.9A patent/EP3662933A1/en not_active Withdrawn
- 2016-03-17 WO PCT/US2016/022943 patent/WO2016149535A1/en not_active Ceased
- 2016-03-17 MX MX2017011432A patent/MX382582B/es unknown
- 2016-03-17 EA EA201792055A patent/EA035374B1/ru unknown
- 2016-03-17 BR BR112017019617-4A patent/BR112017019617A2/pt not_active IP Right Cessation
- 2016-03-17 CN CN201680013161.1A patent/CN107530422B/zh not_active Expired - Fee Related
- 2016-03-17 US US15/557,910 patent/US10722592B2/en active Active
- 2016-03-17 ES ES16765773T patent/ES2795818T3/es active Active
- 2016-03-17 DK DK16765773.3T patent/DK3270965T3/da active
- 2016-03-17 AU AU2016232839A patent/AU2016232839B2/en not_active Ceased
- 2016-03-17 EA EA201992756A patent/EA201992756A3/ru unknown
- 2016-03-17 JP JP2017548953A patent/JP6892826B2/ja not_active Expired - Fee Related
- 2016-03-17 CA CA2976740A patent/CA2976740A1/en not_active Abandoned
- 2016-03-17 SG SG11201706786UA patent/SG11201706786UA/en unknown
-
2017
- 2017-08-16 IL IL254027A patent/IL254027B/en active IP Right Grant
- 2017-08-31 ZA ZA2017/05935A patent/ZA201705935B/en unknown
-
2020
- 2020-05-26 JP JP2020091335A patent/JP2020141700A/ja active Pending
- 2020-06-04 US US16/892,529 patent/US20200289661A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3093327C (en) | Targeted cd73 antibody and antibody-drug conjugate, and preparation method therefor and uses thereof | |
| ES2701188T3 (es) | Conjugados anticuerpo-fármaco e inmunotoxinas | |
| US10752690B2 (en) | Biologically active molecule conjugates, reagents and methods of manufacture, and therapeutic uses | |
| AU2014224928B2 (en) | Amatoxin derivatives | |
| JP5993940B2 (ja) | 生体直交型薬物活性化 | |
| JP2024522389A (ja) | 抗体薬物複合体の調製方法および使用 | |
| ES2939494T3 (es) | Conjugados de fármaco anticuerpo que comprenden derivados de ecteinascidina | |
| CN117295526B (zh) | 制备工程化抗体的高度均质性抗体-药物偶联物的方法 | |
| US20200392108A1 (en) | Antibody-drug conjugates and related compounds, compositions and methods | |
| JP6321687B2 (ja) | アマトキシン誘導体 | |
| JP2016523810A5 (enExample) | ||
| JP2018524373A5 (enExample) | ||
| JP2016531915A5 (enExample) | ||
| JP2014515040A5 (enExample) | ||
| JP2016503295A5 (enExample) | ||
| JP2025517476A5 (enExample) | ||
| JP2022500486A (ja) | 抗体−ａｌｋ５阻害剤コンジュゲートおよびその使用 | |
| FI3525828T3 (fi) | Anti-edb-vasta-aineita ja vasta-aine-lääke-konjugaatteja | |
| JP2019534706A5 (enExample) | ||
| JP7854462B2 (ja) | 抗体－ａｌｋ５阻害剤コンジュゲートおよびその使用 | |
| WO2023163227A1 (ja) | 抗体－薬物コンジュゲート | |
| EA201892343A1 (ru) | Новые в7-н3 связывающие молекулы, содержащие их конъюгаты антитело-лекарственное средство и способы их применения | |
| NZ773646A (en) | Amatoxin-antibody conjugates | |
| NZ730450B2 (en) | Binding molecules, especially antibodies, binding to l1cam (cd171) | |
| NZ773646B2 (en) | Amatoxin-antibody conjugates |